Clinical trial NCT03070574: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Official title: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Colorectal Cancer
Keywords: Lynch Syndrome
Chemoprevention
Mesalazine
5-ASA
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: Prof. Dr. Gabriela Möslein, Germany
name: Prof. Dr. Hans Vasen, The Netherlands
name: Prof. Dr. med. Jan Lubinski, Poland
name: Prof. Dr. med. Yaron Niv, Israel
name: Univ. Prof. Dr. Judith Karner-Hanusch, Austria
name: Ann-Sofie Backman, MD PhD, Sweden
First posted: 2017-03-03
Enrollment: 8
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.

Detailed description: This is a multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine (5-ASA), 1200mg mesalamine (5-ASA) or placebo in LS patients for a 2-year treatment. 540 tumor free carriers of a known genetic mutation in a major MMR gene (including patients in which the polyps are endoscopically removed) will be randomized 1:1:1 (180 each) to receive 2400mg mesalamine, 1200mg mesalamine or placebo. Patients will be identified through local or national registries and through collaboration with sites. Tumor free patients, assessed by white light high resolution colonoscopy, will be randomized to the study. A serum and stool sample will be taken to identify for mesalamine compliance and potential biomarkers. Biopsies of the normal tissue of ascending colon and rectum will be taken at the first and the last colonoscopy.

The aim of the study is to investigate the effect of regular treatment with mesalamine (5-ASA) on the occurrence of any colorectal neoplasia, tumor multiplicity (the number of detected adenomas/carcinomas) and tumor progression in LS patients.

A 50% reduction of the occurrence of colorectal neoplasia in mesalamine-treated patients is expected. Tumor multiplicity and tumor progression (severity of the neoplastic lesions) will be investigated.

Eligibility criteria: Inclusion Criteria:

* Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation on one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
* Male or female subjects with the age \> 25 years
* Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized/vasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period. Females of childbearing potential must have a negative pregnancy test at screening and before randomization.
* Signed written informed consent prior to inclusion in the study

Exclusion Criteria:

* Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)
* Carriers of germline mutations in PMS2
* Patients with history of stage 3 and 4 colorectal cancer (CRC) are excluded
* Presence of metastatic disease
* Regular use of acetylsalicylic acid (ASA or aspirin): daily use of ≥100mg in more than 3 continuous months within the last year
* Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year
* Hypersensitivity to 5-ASA
* Patients after total or subtotal colectomy
* Colorectal surgery within the previous 6 months
* Unwillingness to participate or who is considered incompetent to give an informed consent
* Pregnant or breastfeeding women
* Participation in another clinical study investigating another IMP within 3 months prior to screening
* Renal insufficiency (GFR \<30ml/min/1.73m2)
* Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
* Current or history of serious psychiatric disorder or alcohol/drug abuse that in the opinion of the investigator may impact the assessment of IMP safety andefficacy or protocol adherence
* Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition (such as severe chronic lung (COPD, including asthma), kidney or heart diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, IMP administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study

Primary outcomes:
measure: Reduction in the occurrence of any colorectal neoplasia in LS patients
timeFrame: End of treatment at 24 months +/- 1 month
measure: Reduction in the occurrence of any colorectal neoplasia in LS patients
timeFrame: End of study at year 6 +/- 3 months
Secondary outcomes:
measure: Tumor multiplicity
timeFrame: End of treatment at 24 months +/- 1 month
measure: Tumor progress
timeFrame: End of treatment at 24 months +/- 1 month
measure: Treatment effects
timeFrame: End of treatment at 24 months +/- 1 month
measure: High and low dose ASA
timeFrame: End of treatment at 24 months +/- 1 month
measure: Significant findings & illnesses - adverse events
timeFrame: End of treatment at 24 months +/- 1 month
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Surgery, Medical University Vienna
city: Wuppertal
country: Germany
facility: HELIOS Universitätsklinikum Wuppertal, Zentrum für Hereditäre Tumorerkrankungen
state: Nordrhein-Westfalen
city: Petah Tikva
country: Israel
facility: Rabin Medical Center Beilinson Hospital Gastroenterology Department
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
city: Stettin
country: Poland
facility: Department of Genetics and Pathomorphology of Pomeranian Medical University
city: Solna
country: Sweden
facility: Karolinska universitetsjukhuset, A6:00 Gastroenterologiskt öppenvårdscentrum, Mottagningen för ärftlig tarmcancer
Study officials:
References: